Current Pharmaceutical Biotechnology

Zeno Foldes-Papp
Visiting Professor of Medical Biochemistry
HELIOS Clinical Center of Emergency Medicine
Department for Internal Medicine
Alte-Koelner-Strasse 9
D-51688 Koeln-Wipperfuerth


Progress in Development of Group A Streptococcus Vaccines

Author(s): Yingli Song, Xiaolan Zhang, Chunmei Lu, Fengmin Zhang and Hui Zhu

Affiliation: Department of Physiology, Harbin Medical University, Harbin 150081, China


Streptococcus pyogenes or Group A Streptococcus (GAS) is a major Gram-positive human pathogen that causes diverse human diseases with a high morbidity and mortality worldwide. The development of an effective GAS vaccine is hindered by the occurrence of many unique GAS serotypes, the complexity of the global epidemiology of GAS infections, and safety concerns over the cross-reactivity of some antigen-specific antibodies with human tissues and proteins. Although no licensed GAS vaccine is available, a number of candidate vaccines have been or are being evaluated in laboratory or in clinical trials. This minireview provides brief information on the progress and difficulty in the development of GAS vaccines.

Keywords: Arginine deiminase, Group A Streptococcus, Group A carbohydrate, M protein, ScpA, Shr, SpyCEP, SsE, Streptococcal fibronectin-binding proteins, Streptococcal pyrogenic exotoxins, Trigger factor, Vaccine.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [947 - 950]
Pages: 4
DOI: 10.2174/1389201014666131226125540